To the full analysis
Chemed stock: growth
CHEChemed reported $2.53B in revenue for fiscal 2025, up 4.1% on the prior year, up 4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
4.9%
per year from 2006 to 2025, per share 8.2%
Earnings (Annual rate)
9.1%
per year from 2006 to 2025, per share 12.6%
Free cash flow (Annual rate)
7.9%
per year from 2006 to 2025, per share 11.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 4.0% | 5.1% | 4.9% |
| Revenue per share | 6.2% | 6.7% | 8.2% |
| Earnings | −3.7% | 9.2% | 9.1% |
| Earnings per share | −1.7% | 10.9% | 12.6% |
| Free cash flow | −5.4% | 9.8% | 7.9% |
| Free cash flow per share | −3.5% | 11.6% | 11.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.02B | $50.65M | $76.6M |
| 2007 | $1.1B | $63.98M | $72.94M |
| 2008 | $1.15B | $71.02M | $85.99M |
| 2009 | $1.19B | $73.78M | $139.34M |
| 2010 | $1.28B | $81.83M | $60.37M |
| 2011 | $1.36B | $85.98M | $144.75M |
| 2012 | $1.43B | $89.3M | $96.52M |
| 2013 | $1.41B | $77.23M | $121.52M |
| 2014 | $1.46B | $99.32M | $66.71M |
| 2015 | $1.54B | $110.27M | $127.37M |
| 2016 | $1.58B | $108.74M | $95.62M |
| 2017 | $1.67B | $98.18M | $98.2M |
| 2018 | $1.78B | $205.54M | $234.27M |
| 2019 | $1.94B | $219.92M | $248.23M |
| 2020 | $2.08B | $319.47M | $430.46M |
| 2021 | $2.14B | $268.55M | $249.92M |
| 2022 | $2.13B | $249.62M | $252.56M |
| 2023 | $2.26B | $272.51M | $273.45M |
| 2024 | $2.43B | $302M | $367.97M |
| 2025 | $2.53B | $265.24M | $325.48M |
Revenue by segment
How Chemed Corporation makes its money and how that has shifted. Names are as the company reports them.
- Segment Vitas$1.7B67%
- Segment Roto Rooter$937.9M37%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Segment Vitas | $1.69B | 66.7% |
| Segment Roto Rooter | $937.92M | 37.1% |
| Total revenue | $2.53B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 26 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.